Karuna Therapeutics Inc KRTX:NASDAQ

Last Price$262.50Cboe Real-Time Last Sale as of 9:57AM ET 8/17/22
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change-1.19(0.45%)
Bid (Size)$261.19 (1)
Ask (Size)$262.75 (5)
Day Low / High$256.65 - 262.50
Volume34.4 K
 

View Pharmaceuticals: Major IndustryPeer Comparison as of 08/17/2022

 

Karuna Therapeutics Inc ( NASDAQ )

Price: $262.50
Change: -1.19 (0.45%)
Volume: 34.4 K
9:57AM ET 8/17/2022
 
 

Apellis Pharmaceuticals Inc ( NASDAQ )

Price: $68.10
Change: -0.31 (0.45%)
Volume: 26.2 K
9:57AM ET 8/17/2022
 
 

Sarepta Therapeutics Inc ( NASDAQ )

Price: $108.20
Change: +0.37 (0.34%)
Volume: 19.5 K
9:57AM ET 8/17/2022
 
 

Ionis Pharmaceuticals Inc ( NASDAQ )

Price: $44.22
Change: -0.10 (0.23%)
Volume: 29.7 K
9:56AM ET 8/17/2022
 
 

United Therapeutics Corp ( NASDAQ )

Price: $220.70
Change: -0.96 (0.43%)
Volume: 6.2 K
9:57AM ET 8/17/2022
 

Read more news Recent News

Insider Sell: Karuna Therapeutics
4:10PM ET 8/16/2022 MT Newswires

Laurie J Olson, Director, on August 15, 2022, sold 1,000 shares in Karuna Therapeutics (KRTX) for $267,590. SEC Filing:...

HC Wainwright Adjusts Price Target on Karuna Therapeutics to $320 From $160, Reiterates Buy Rating
8:25AM ET 8/15/2022 MT Newswires

Karuna Therapeutics (KRTX) has an average rating of buy and price targets ranging from $160 to $332, according to analysts polled by Capital IQ. (MT...

--Guggenheim Adjusts Price Target on Karuna Therapeutics to $330 From $200, Reiterates Buy Rating
9:24AM ET 8/12/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

--RBC Raises Price Target on Karuna Therapeutics to $292 From $160, Calls Data on KarXT in Schizophrenia 'Transformative,' Keeps Outperform-Speculative Risk Rating
8:08AM ET 8/12/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Company Profile

Business DescriptionKaruna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. engages in business of research and development of therapies utilizing muscarinic cholinergic receptors to treat psychosis and cognitive impairment in numerous central nervous system disorders. The company was founded by Andrew Miller, Eric Elenko, and Peter Jeffrey Conn in July 2009 and is headquartered in Boston, MA. View company web site for more details
Address99 High Street
Boston, Massachusetts 02110
Phone+1.857.449.2244
Number of EmployeesN/A
Chairman, President & Chief Executive OfficerSteven Marc Paul
Chief Operating OfficerAndrew Miller
Chief Financial Officer & SecretaryTroy A. Ignelzi
Chief Medical OfficerStephen Brannan

Company Highlights

Price Open$257.95
Previous Close$263.69
52 Week Range$92.26 - 278.25
Market Capitalization$7.9 B
Shares Outstanding30.0 M
SectorHealth Technology
IndustryPharmaceuticals: Major
Next Earnings Announcement11/03/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$6.79
Beta vs. S&P 500N/A
Revenue$0.00
Net Profit Margin-478.32%
Return on Equity-43.00%

Analyst Ratings as of 08/09/2022

Buy
17
Overweight
0
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset